WVU and Irish company are partners in prostate cancer research

WVU Center for Advanced Imaging and SensL developing biopsy tool

MORGANTOWN, W.Va. – SensL, an Irish technology company that specializes in devices that can detect extremely faint light has partnered with biomedical researchers at West Virginia University to begin development of a new medical imaging tool for prostate cancer biopsies.

WVU’s Center for Advanced Imaging has been studying the use of positron emission tomography (PET) in combination with other imaging technologies to advance the development of new diagnostic tools, particularly in detecting small cancers in the breast, prostate and brain. SensL, based in Cork, Ireland, has developed low profile silicon photomultiplier detector technology that is small enough to be included in one of WVU’s prototype medical devices.

“There is a clear need for the prostate probe to aid in biopsy procedures for the prostate,” said Dr. Mohamad Salkini, director of robotics & minimally invasive surgery in the WVU School of Medicine. “The prostate imager would revolutionize prostate biopsy procedures by reduction of the false negative rate and minimizing the amount of samples required for cancer detection.”

According to the AdMe Tech Foundation (www.admetech.org), prostate cancer affects 1 in 6 males, and biopsies which are not guided or performed “blindly” miss at least 20 percent of cancers. Additionally, the cost of unnecessary biopsy procedures is over $2 billion in the U.S. alone.


SensL media release:



For more information:
Amy Johns, HSC News Service, 304-293-7087
bc: 11-24-09

Return To News Releases